Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study
文摘
SA4Ag is a novel multiantigen vaccine that targets S. aureus virulence factors. A single dose of SA4Ag was well-tolerated in healthy adults aged 18–64 years. A robust functional immune response was elicited to each vaccine component. Antibody rise was rapid and sustained after one dose of SA4Ag vaccine. SA4Ag is a promising candidate vaccine to prevent invasive S. aureus infections.